Switching from warfarin to DOACs in frail elderly Asian AF patients was linked to higher risks of adverse clinical events compared to continuing warfarin.
Does switching from warfarin to DOACs reduce adverse clinical events in frail elderly Asian patients with atrial fibrillation stably maintained on warfarin?
In frail elderly Asian patients with atrial fibrillation who are stable on warfarin, switching to DOACs may increase the risk of adverse clinical events.
Absolute Event Rate: 0% vs 0%
In frail elderly Asian AF patients stably maintained on warfarin, switching to DOACs was associated with higher risks of adverse clinical events, suggesting the need for careful consideration before routine switching.
“Switching from a VKA to a NOAC should not be considered without a clear indication in frail older patients with atrial fibrillation.”
Lee et al. (Thu,) reported a other. Switching from warfarin to DOACs in frail elderly Asian AF patients was linked to higher risks of adverse clinical events compared to continuing warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: